First mRNA vaccine for genital herpes enters human testing
NCT ID NCT07330440
Summary
This is an early-stage study to test the safety and immune response of a new mRNA vaccine designed to protect against genital herpes (HSV-2). It will enroll 144 healthy adults, testing different vaccine doses in people who have never had the virus and those who have. The main goal is to see if the vaccine is safe and well-tolerated, and to measure the body's immune reaction to it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENITAL HERPES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Jishuitan Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.